Intuniv Shortage Update: What Patients Need to Know in 2026

If your child takes Intuniv and you've had trouble filling the prescription, you're not imagining it. Even though Intuniv is not officially listed on the FDA's Drug Shortage database for the U.S. market in 2026, patients and caregivers across the country continue to report difficulty finding it at their local pharmacy. Here's what you need to know.

Is There an Official Intuniv Shortage in 2026?

As of early 2026, the FDA does not list Intuniv (guanfacine ER) or its generic equivalents on the official U.S. Drug Shortage database. This is significantly different from the stimulant ADHD medications — Adderall and methylphenidate — which remain in formal FDA shortage.

The reason Intuniv is less vulnerable to formal shortages is structural: it is not a controlled substance and is not subject to DEA annual production quotas. Manufacturers can produce as much as the market demands without hitting a regulatory cap.

What About the 2023 Intuniv Shortage?

In September 2023, a significant supply disruption of Intuniv occurred — but primarily in the United Kingdom, not the United States. Takeda, the brand manufacturer at the time, issued a healthcare professional letter advising against initiating new patients on any strength of Intuniv until the supply interruption was resolved. The affected strengths included 1 mg, 2 mg, 3 mg, and 4 mg tablets.

Takeda reported that supplies were expected to return in late November and early December 2023. By 2024, the UK supply situation had largely resolved, and the NHS Specialist Pharmacy Service updated its guidance accordingly.

In the U.S., this supply disruption had minimal direct impact since American pharmacies sourced from different manufacturers and distributors.

Why Are Some Patients Still Having Trouble Finding Intuniv?

Even without a formal national shortage, several factors create pharmacy-level stockouts:

• Stimulant shortage spillover. The ongoing shortage of amphetamine and methylphenidate medications has significantly increased demand for non-stimulant ADHD drugs like Intuniv. Pharmacies that weren't stocking large quantities are being caught off-guard by this demand increase.
• Adjunctive use patterns. Intuniv is increasingly prescribed alongside stimulant medications to enhance their effectiveness and reduce side effects. This adjunct use has added to overall demand.
• Generic fragmentation. Multiple generic manufacturers now produce guanfacine ER. Pharmacies may carry only one manufacturer's version, and if that specific manufacturer has a backorder, the pharmacy shows as out-of-stock even while other generics are available elsewhere.
• Dose-specific gaps. Higher doses (3 mg and 4 mg) tend to have fewer generic manufacturers competing, which can create regional gaps in availability.

Availability by Region and Formulation

As of 2026, Intuniv availability in the U.S. varies by:

• Strength: 1 mg and 2 mg are generally easier to find; 3 mg and 4 mg can be harder to locate at some pharmacies
• Brand vs. generic: Brand Intuniv is less commonly stocked; generic guanfacine ER is more widely available
• Pharmacy type: Independent pharmacies may have different availability than large chain pharmacies
• Region: Urban areas with more pharmacy options generally offer more choices; rural areas may face longer waits for restocking

Critical Warning: Never Stop Intuniv Suddenly

This cannot be stressed enough: Intuniv (guanfacine ER) affects blood pressure and heart rate. Abrupt discontinuation can cause rebound hypertension — a sudden spike in blood pressure that can be medically dangerous. If you cannot get your prescription filled on time, call your prescriber immediately. Do not simply skip doses without guidance.

What Patients Can Do Right Now

Here are practical steps to take if you're having trouble filling Intuniv:

1. Start searching early. Contact pharmacies 3-5 days before you need a refill, not the day of.
2. Use medfinder. medfinder calls pharmacies near you to check availability, so you don't have to spend time on hold.
3. Try independent pharmacies. Local independents often source from different distributors than chain pharmacies.
4. Consider mail-order. Intuniv is not a controlled substance, so mail-order pharmacy (including 90-day fills) is fully available and can bypass local stocking issues.
5. Talk to your prescriber. If a specific strength is hard to find, your doctor may have clinical flexibility (e.g., prescribing two 1 mg tablets instead of a 2 mg) or can suggest an alternative.

Bottom Line

Intuniv is not in a formal U.S. shortage in 2026, but localized stocking gaps are real and driven by increased demand. Acting early, broadening your pharmacy search, and using tools like medfinder are your best strategies. For background on why this happens, see why Intuniv is hard to find. If the search keeps failing, see our guide to alternatives to Intuniv.